tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-2-oxoazepan-3-yl]carbamate | 781650-32-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-2-oxoazepan-3-yl]carbamate
• 英文别名: tert-butyl N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxoazepan-3-yl]carbamate
• CAS: 781650-32-6
• 化学式: C₁₇H₂₂F₂N₂O₃
• 分子量: 340.37
• InChiKey: WCOPAMRQAVLNBD-ZWNOBZJWSA-N

物化性质

• 沸点：
  491.0±45.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-2-oxoazepan-3-yl]carbamate 在 劳森试剂 、 重铬酸吡啶 、 三氟乙酸 、 mercury dichloride 作用下， 以 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 tert-butyl (6S,9R)-6-(2,3-difluorophenyl)-3-(1-methoxy-1-methylethyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-9-ylcarbamate
  参考文献：
  名称：

  Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918

  摘要：

  In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.054
• 作为产物：
  描述：

  benzyl (5S)-N,N-bis(tert-butoxycarbonyl)-5-(2,3-difluorophenyl)-6-nitro-D-norleucinate 在 palladium 10% on activated carbon N-羟基-7-氮杂苯并三氮唑 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 37.0h， 生成 tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-2-oxoazepan-3-yl]carbamate
  参考文献：
  名称：

  WO2008/153849

  摘要：

  公开号：

文献信息

• Cgrp Receptor Antagonists
  申请人：Burgey S. Christopher

  公开号：US20070287696A1

  公开（公告）日：2007-12-13

  Compounds of Formula I: and Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, D, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, pharmaceutical compositions comprising these compounds, use of these compounds and compositions to prevent or treat diseases involving CGRP.

  化合物的化学式I：和化学式II：（其中变量R1、R2、R3、R4、A、B、D、G、J、Q、T、W、X和Y的定义如下）可作为CGRP受体拮抗剂，在涉及CGRP的疾病的治疗或预防中有用，包括这些化合物的药物组合物、使用这些化合物和组合物来预防或治疗涉及CGRP的疾病。
• CGRP receptor antagonists
  申请人：Burgey S. Christopher

  公开号：US20050256098A1

  公开（公告）日：2005-11-17

  The present invention is directed to compounds of Formula I: and Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I和式II的化合物：（其中变量R1、R2、R3、R4、A、B、G、J、Q、T、U、V、W、X和Y如此定义），这些化合物可用作CGRP受体的拮抗剂，并可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗参与CGRP的这些疾病。
• Carboxamide Spirolactam Cgrp Receptor Antagonists
  申请人：Williams M. Theresa

  公开号：US20070293470A1

  公开（公告）日：2007-12-20

  The present invention is directed to compounds of Formula I: I (where variables A 1 , A 2 , B, J, K, m, n, R 4 , R 5a , R 5b and R 5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中变量A1、A2、B、J、K、m、n、R4、R5a、R5b和R5c如本文所定义），用作CGRP受体的拮抗剂，并用于治疗或预防涉及CGRP的疾病，例如头痛、偏头痛和群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP的疾病中的使用。
• Carboxamide spirolactam CGRP receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US07390798B2

  公开（公告）日：2008-06-24

  The present invention is directed to compounds of Formula I: I (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved

  本发明涉及式I的化合物：I（其中变量A1，A2，B，J，K，m，n，R4，R5a，R5b和R5c的定义如本文所述），其作为CGRP受体拮抗剂在治疗或预防CGRP参与的疾病，例如头痛，偏头痛和群头痛方面有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病方面使用这些化合物和组合物。
• CGRP RECEPTOR ANTAGONISTS
  申请人：Burgey Christopher S.

  公开号：US20100113419A1

  公开（公告）日：2010-05-06

  The present invention is directed to compounds of Formula I: Formula I: Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及I式化合物：I式：II式：（其中变量R1、R2、R3、R4、A、B、J、Q、T、V、W、X和Y的定义如本文所述），用作CGRP受体拮抗剂，有助于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗CGRP参与的疾病方面的使用。